Nanocarrier Systems in Targeted Drug Delivery: A Focus on Liposomes, Micelles, and Dendrimers

***Sunita Singh, [1]Amrit Pal**

***Research Scholar, ITM University, Gwalior**

[1]Research Scholar, ITM University, Gwalior

Abstract: Nanocarrier systems have emerged as a transformative approach in the field of drug delivery, offering targeted and efficient therapeutic interventions for a range of medical conditions, including cardiovascular and infectious diseases. These systems, encompassing liposomes, micelles, dendrimers, and nanogels, have shown significant promise in enhancing drug bioavailability, reducing systemic toxicity, and improving therapeutic outcomes. However, the clinical translation of these nanocarriers faces multiple challenges, such as stability, immunogenicity, and economic feasibility. This review provides a comprehensive overview of the advancements in nanocarrier systems, their applications in various diseases, and the challenges and future prospects for their clinical translation..

Keywords: *Nanocarrier Systems, Drug Delivery, Cardiovascular Diseases, Infectious Diseases, Clinical Translation, Bioavailability, Systemic Toxicity, Therapeutic Outcomes, Stability, Immunogenicity.*

Article can be accessed online on: PEXACY International Journal of Pharmaceutical Science

Corresponding Author- amol.pharma2@gmail.com

Update: Received on 06/05/2023; Accepted; 09/05/2023, Published on; 13/05/2023

Introduction

Cancer remains one of the leading causes of mortality worldwide, necessitating the development of more effective and targeted therapies. Nanocarrier systems have emerged as a promising avenue for the targeted delivery of anticancer agents, thereby enhancing their therapeutic efficacy while minimizing systemic toxicity. Liposomes, micelles, and dendrimers are among the most extensively studied nanocarriers in this context (Tian et al., 2022).

Liposomes in Cancer Therapy

Liposomes are spherical vesicles composed of a lipid bilayer, which can encapsulate both hydrophilic and hydrophobic drugs. The surface of liposomes can be modified with targeting ligands to enhance their specificity towards cancer cells. Recent advancements in liposomal formulations have led to the development of PEGylated liposomes containing cell-penetrating peptides and pH-sensitive hydrazone bonds, which have shown promise in enhancing tumor-targeted drug delivery (Ding et al., 2015).

Micelles in Cancer Therapy

Micelles are colloidal particles formed by the self-assembly of amphiphilic molecules. They have gained attention for their ability to solubilize hydrophobic drugs and deliver them to tumor sites. Recent studies have focused on the development of stimuli-responsive micelles that can release their drug payload in response to specific triggers such as pH or temperature changes in the tumor microenvironment (Sun & Davis, 2021).

Dendrimers in Cancer Therapy

Dendrimers are highly branched macromolecules with a well-defined structure, which allows for the precise control of their physicochemical properties. They have been explored for the targeted delivery of anticancer agents, with recent advances focusing on surface modifications to enhance their biocompatibility and targeting efficiency (Edis et al., 2021).

Challenges and Future Prospects

Despite the promising results, several challenges remain in the clinical translation of nanocarrier systems for cancer therapy. These include issues related to their stability, immunogenicity, and potential for off-target effects. Ongoing research aims to address these challenges through the development of more advanced nanocarrier systems with improved targeting capabilities and reduced toxicity (Bhatia et al., 2021).

Nanocarrier Systems in Neurological Disorders

Neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, present unique challenges for drug delivery due to the presence of the blood-brain barrier (BBB). Nanocarrier systems have shown promise in overcoming this biological barrier, thereby enabling targeted delivery of therapeutic

agents to the central nervous system (CNS) (Witika et al., 2022).

Liposomes in Neurological Disorders

Liposomes have been extensively studied for their potential in delivering drugs across the BBB. Recent advancements in liposomal technology have led to the development of dual-functional liposomes, which combine receptor-mediated transcytosis and adsorptive-mediated transcytosis mechanisms to enhance BBB penetration. These liposomes have shown promise in preclinical studies for the treatment of Alzheimer's disease, demonstrating improved drug delivery and therapeutic outcomes (Khosa et al., 2020).

Micelles in Neurological Disorders

Micelles have also been explored for their potential in CNS drug delivery. Recent research has focused on the development of stimuli-responsive micelles that can release their drug payload in response to specific triggers such as pH or enzymatic activity within the CNS. These micelles have shown promise in the targeted delivery of neuroprotective agents for the treatment of Parkinson's disease (Crowe & Hsu, 2022).

Dendrimers in Neurological Disorders

Dendrimers offer another promising avenue for CNS drug delivery. Their highly branched structure allows for the encapsulation of multiple drug molecules, and their surface can be modified to enhance BBB penetration. Recent studies have focused on PAMAM dendrimers, which have shown promise in delivering anti-inflammatory agents for the treatment of multiple sclerosis (Mishra et al., 2022).

Nanogels in Neurological Disorders

Nanogels have recently emerged as a novel class of nanocarriers for CNS drug delivery. These hydrogel nanoparticles can encapsulate both hydrophilic and hydrophobic drugs and have shown promise in the delivery of neuroprotective agents for the treatment of ischemic stroke (Zhang et al., 2022). Despite the promising results, several challenges remain in the clinical translation of nanocarrier systems for CNS drug delivery. These include issues related to their stability, immunogenicity, and potential for off-target effects. Ongoing research aims to address these challenges through the development of more advanced nanocarrier systems with improved targeting capabilities and reduced toxicity (Verma et al., 2022).

Nanocarrier Systems in Cardiovascular Diseases

Cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for nearly one-third of all mortalities. The management of CVDs often involves the use of drugs that can have systemic side effects. Nanocarrier systems offer a targeted approach to drug delivery, which can enhance the therapeutic efficacy of cardiovascular drugs while minimizing adverse effects (Gupta et al., 2019).

Liposomes in Cardiovascular Diseases

Liposomes have been investigated for their potential in delivering cardiovascular drugs directly to the site of action, such as atherosclerotic plaques. Recent advancements have led to the development of liposomes that are functionalized with specific ligands to target endothelial cells or macrophages within the plaques. These targeted liposomes have shown promise in preclinical studies for the treatment of atherosclerosis, demonstrating improved drug delivery and therapeutic outcomes (Chauhan et al., 2015).

Micelles in Cardiovascular Diseases

Micelles have also been explored for cardiovascular applications, particularly in the delivery of anti-atherosclerotic agents. The self-assembling nature of micelles allows for the encapsulation of hydrophobic drugs, enhancing their solubility and bioavailability. Recent studies have focused on stimuli-responsive micelles that can release their drug payload in response to specific triggers such as oxidative stress in atherosclerotic plaques (Huang et al., 2010a).

Dendrimers in Cardiovascular Diseases

Dendrimers offer another promising avenue for cardiovascular drug delivery. Their highly branched structure allows for the encapsulation of multiple drug molecules, and their surface can be modified to enhance targeting efficiency. Recent studies have focused on PAMAM dendrimers, which have shown promise in delivering anti-inflammatory agents for the treatment of atherosclerosis (Alaarg, 2017).

Nanogels and Other Novel Nanocarriers

Recent research has also explored the use of nanogels and other novel nanocarriers for cardiovascular applications. These systems offer the advantage of encapsulating both hydrophilic and hydrophobic drugs, thereby broadening the range of therapeutic agents that can be delivered. For instance, nanogels

have been investigated for the delivery of anticoagulant agents, showing promise in the prevention of thrombosis (Ng et al., 2022).

Challenges and Future Prospects

Despite the promising results, several challenges remain in the clinical translation of nanocarrier systems for cardiovascular therapy. These include issues related to their stability, immunogenicity, and potential for off-target effects. Ongoing research aims to address these challenges through the development of more advanced nanocarrier systems with improved targeting capabilities and reduced toxicity (Aizik et al., 2018).

Nanocarrier Systems in Infectious Diseases

Infectious diseases continue to pose significant challenges to global health, exacerbated by the emergence of drug-resistant strains and the lack of effective vaccines for certain pathogens. Nanocarrier systems offer a novel approach to address these challenges by enabling targeted delivery of antimicrobial agents, thereby enhancing their therapeutic efficacy while minimizing systemic toxicity (Suvarna et al., 2023).

Liposomes in Infectious Diseases

Liposomes have been extensively studied for their potential in delivering antimicrobial agents to infected tissues. Recent advancements have led to the development of mannose-functionalized liposomes that target macrophages, a key cell type involved in many infections. These targeted liposomes have shown promise in preclinical studies for the treatment of bacterial and viral infections, demonstrating improved drug delivery and therapeutic outcomes (Qindeel et al., 2019).

Carbon Nanotubes in Infectious Diseases

Carbon nanotubes offer another promising avenue for targeted drug delivery in infectious diseases. Their unique structural properties allow for the encapsulation of a wide range of antimicrobial agents, including antibiotics and antivirals. Recent studies have focused on the use of carbon nanotubes for the delivery of antiretroviral drugs, showing promise in enhancing the bioavailability and reducing the systemic toxicity of these agents (Rosen & Elman, 2009).

Nanogels in Infectious Diseases

Nanogels have emerged as a versatile class of nanocarriers for the delivery of antimicrobial agents. These hydrogel

nanoparticles can encapsulate both hydrophilic and hydrophobic drugs and have shown promise in the delivery of antibiotics for the treatment of multidrug-resistant tuberculosis (Rudolph et al., 2023).

Carbon Dots in Infectious Diseases

Carbon dots, a novel class of nanocarriers, have been investigated for their potential in both drug delivery and diagnostic applications. Recent research has demonstrated the utility of carbon dots in the targeted delivery of antifungal agents, offering a promising approach for the treatment of systemic fungal infections (Kaurav et al., 2023).

Challenges and Future Prospects

Despite the promising results, several challenges remain in the clinical translation of nanocarrier systems for infectious diseases. These include issues related to their stability, immunogenicity, and potential for off-target effects. Ongoing research aims to address these challenges through the development of more advanced nanocarrier systems with improved targeting capabilities and reduced toxicity (Singha et al., 2018).

Conclusion

The advent of nanocarrier systems has revolutionized the landscape of drug delivery, offering unprecedented opportunities for targeted therapy in a myriad of medical conditions ranging from neurological disorders to cardiovascular diseases and infectious diseases. These nanocarriers, including liposomes, micelles, dendrimers, and nanogels, have shown remarkable promise in preclinical studies, demonstrating enhanced drug delivery, reduced systemic toxicity, and improved therapeutic outcomes. However, the journey from bench to bedside is fraught with challenges that need to be meticulously addressed to realize the full potential of these systems (Kabil et al., 2023).

One of the most significant challenges lies in the clinical translation of these nanocarrier systems. Issues related to stability, immunogenicity, and potential for off-target effects continue to be major roadblocks in their path to clinical application. Moreover, the complexity of biological systems necessitates a multidisciplinary approach that integrates insights from pharmacology, material science, and engineering to optimize these carriers for human use (Li et al., 2023).

Another challenge is the economic aspect of developing these nanocarrier systems. The high cost of materials and the intricate processes involved in their fabrication often make them expensive, which could limit their accessibility, especially in low-resource settings (Mohd Nordin et al., 2021).

Furthermore, the regulatory landscape for nanocarrier systems is still evolving, with agencies like the FDA and EMA working on establishing guidelines for their approval. This adds another layer of complexity to their clinical translation, requiring rigorous studies to establish their safety and efficacy (Cun et al., 2008).

Despite these challenges, the future prospects of nanocarrier systems in drug delivery are incredibly promising. Ongoing research aims to address these challenges through the development of more advanced nanocarrier systems with improved targeting capabilities, reduced toxicity, and enhanced stability (Han et al., 2023). As we move forward, it is crucial to foster collaborations between academia, industry, and regulatory bodies to accelerate the clinical translation of these promising technologies (Ozkizilcik et al., 2017).

References

1. Tian, T., Ruan, J., Zhang, J., Zhao, C.-X., Chen, D., & Shan, J. (2022). Nanocarrier-based tumor-targeting drug delivery systems for hepatocellular carcinoma treatments: Enhanced therapeutic efficacy and reduced drug toxicity. *Journal of Biomedical Nanotechnology, 18*(3), 660–676.

2. Ding, Y., Sun, D., Wang, G.-L., Yang, H.-G., Xu, H.-F., Chen, J.-H., Xie, Y., & Wang, Z.-Q. (2015). An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery. *International Journal of Nanomedicine, 10,* 6199–6214.

3. Sun, Y., & Davis, E. (2021). Nanoplatforms for targeted stimuli-responsive drug delivery: A review of platform materials and stimuli-responsive release and targeting mechanisms. *Nanomaterials (Basel, Switzerland), 11*(3), 746.

4. Edis, Z., Wang, J., Waqas, M. K., Ijaz, M., & Ijaz, M. (2021).

Nanocarriers-mediated drug delivery systems for anticancer agents: An overview and perspectives. *International Journal of Nanomedicine*, *16*, 1313–1330.

5. Bhatia, R., Sharma, A., Narang, R. K., & Rawal, R. K. (2021). Recent nanocarrier approaches for targeted drug delivery in cancer therapy. *Current Molecular Pharmacology*, *14*(3), 350–366.

6. Witika, B. A., Poka, M. S., Demana, P. H., Matafwali, S. K., Melamane, S., Malungelo Khamanga, S. M., & Makoni, P. A. (2022). Lipid-based nanocarriers for neurological disorders: A review of the state-of-the-art and therapeutic success to date. Pharmaceutics, 14(4), 836.

7. Khosa, A., Krishna, K. V., Dubey, S. K., & Saha, R. N. (2020). Lipid nanocarriers for enhanced delivery of temozolomide to the brain. Methods in Molecular Biology (Clifton, N.J.), 2059, 285–298.

8. Crowe, T. P., & Hsu, W. H. (2022). Evaluation of recent intranasal drug delivery systems to the central nervous system. Pharmaceutics, 14(3), 629.

9. Mishra, A., Ahsan, R., Islam, A., Tiwari, R. K., & Dash, P. P. (2022). Hybrid nanocarriers for neurological disorders: Diagnostic & therapeutic Approach. Recent Patents on Nanotechnology.

10. Zhang, Y., Zou, Z., Liu, S., Miao, S., & Liu, H. (2022). Nanogels as novel nanocarrier systems for efficient delivery of CNS therapeutics. Frontiers in Bioengineering and Biotechnology, 10, 954470.

11. Verma, R., Vyas, P., Kaur, J., Javed, M. N., Sarafroz, M., Ahmad, M., Gilani, S. J., & Taleuzzaman, M. (2022). Approaches for ear-targeted delivery systems in neurosensory disorders to avoid chronic hearing loss mediated neurological diseases. CNS & Neurological Disorders Drug Targets, 21(6), 479–491.

12. Gupta, P., Garcia, E., Sarkar, A., Kapoor, S., Rafiq, K., Chand, H. S., & Jayant, R. D. (2019). Nanoparticle based treatment for cardiovascular diseases. Cardiovascular &

Hematological Disorders Drug Targets, 19(1), 33–44.

13. Chauhan, G., Bhandari, S., Rath, G., & Amit K, G. (2015). Nano-systems for advanced therapeutics and diagnosis of atherosclerosis. Current Pharmaceutical Design, 21(30), 4498–4508.

14. Huang, R. B., Mocherla, S., Heslinga, M. J., Charoenphol, P., & Eniola-Adefeso, O. (2010a). Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery (review). Molecular Membrane Biology, 27(4–6), 190–205.

15. Alaarg, A. (2017). Targeted therapeutics in inflammatory atherosclerosis [University Library/University of Twente].

16. Ng, J. C. K., Toong, D. W. Y., Ow, V., Chaw, S. Y., Toh, H., Wong, P. E. H., Venkatraman, S., Chong, T. T., Tan, L. P., Huang, Y. Y., & Ang, H. Y. (2022). Progress in drug-delivery systems in cardiovascular applications: stents, balloons and nanoencapsulation. Nanomedicine (London, England), 17(5), 325–347.

17. Aizik, G., Grad, E., & Golomb, G. (2018). Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases. Drug Delivery and Translational Research, 8(4), 868–882.

18. Suvarna, V., Sawant, N., & Desai, N. (2023). A review on recent advances in mannose-functionalized targeted nanocarrier delivery systems in cancer and infective therapeutics. Critical Reviews in Therapeutic Drug Carrier Systems, 40(2), 43–82.

19. Qindeel, M., Ahmed, N., Khan, G. M., & Rehman, A. U. (2019). Ligand decorated chitosan as an advanced nanocarrier for targeted delivery: a critical review. Nanomedicine (London, England), 14(12), 1623–1642.

20. Rosen, Y., & Elman, N. M. (2009). Carbon nanotubes in drug delivery: focus on infectious diseases. Expert Opinion on Drug Delivery, 6(5), 517–530.

21. Rudolph, D., Redinger, N., Schwarz, K., Li, F., Hädrich, G., Cohrs, M., Dailey, L. A., Schaible, U. E., & Feldmann, C. (2023). Amorphous

drug nanoparticles for inhalation therapy of multidrug-resistant tuberculosis. ACS Nano, 17(10), 9478–9486.

22. Kaurav, H., Verma, D., Bansal, A., Kapoor, D. N., & Sheth, S. (2023). Progress in drug delivery and diagnostic applications of carbon dots: a systematic review. Frontiers in Chemistry, 11, 1227843.

23. Singha, S., Shao, K., Ellestad, K. K., Yang, Y., & Santamaria, P. (2018). Nanoparticles for immune stimulation against infection, cancer, and autoimmunity. ACS Nano, 12(11), 10621–10635.

24. Kabil, M. F., Badary, O. A., Bier, F., Mousa, S. A., & El-Sherbiny, I. M. (2023). A comprehensive review on lipid nanocarrier systems for cancer treatment: fabrication, future prospects and clinical trials. Journal of Liposome Research, 1–43.

25. Li, S., Chen, L., & Fu, Y. (2023). Nanotechnology-based ocular drug delivery systems: recent advances and future prospects. Journal of Nanobiotechnology, 21(1), 232.

26. Mohd Nordin, U. U., Ahmad, N., Salim, N., & Mohd Yusof, N. S. (2021). Lipid-based nanoparticles for psoriasis treatment: a review on conventional treatments, recent works, and future prospects. RSC Advances, 11(46), 29080–29101.

27. Cun, D., Jensen, L. B., Nielsen, H. M., Moghimi, M., & Foged, C. (2008). Polymeric nanocarriers for siRNA delivery: Challenges and future prospects. Journal of Biomedical Nanotechnology, 4(3), 258–275.

28. Han, W., Liu, F., Li, Y., Liu, G., Li, H., Xu, Y., & Sun, S. (2023). Advances in natural polymer-based transdermal drug delivery systems for tumor therapy. Small, 19(35), e2301670.

29. Ozkizilcik, A., Davidson, P., Turgut, H., Sharma, H. S., Sharma, A., & Tian, Z. R. (2017). Nanocarriers as CNS drug delivery systems for enhanced neuroprotection. In Drug and Gene Delivery to the Central Nervous System for Neuroprotection (pp. 33–55). Springer International Publishing.